行情

ENTA

ENTA

Enanta制药
NASDAQ

实时行情|Nasdaq Last Sale

49.10
-1.24
-2.46%
交易中 12:15 04/02 EDT
开盘
49.97
昨收
50.34
最高
50.77
最低
47.36
成交量
5.33万
成交额
--
52周最高
101.27
52周最低
38.40
市值
9.78亿
市盈率(TTM)
30.36
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ENTA价格均价为83.40,最高价位130.00,最低价为47.00。

EPS

ENTA 新闻

更多
  • 特朗普料俄罗斯和沙特大规模减产 原油价格飙升
  • 新浪财经 · 1小时前
  • 瑞幸在割美国韭菜吗?前十大持仓基金究竟是谁?
  • 新浪财经 · 1小时前
  • 石油股大涨,因特朗普预期俄罗斯和沙特将减产
  • 新浪财经 · 1小时前
  • 石油三国杀要结束了?还言之尚早
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
+2.27%
制药与医学研究
+1.78%

热门股票

代码
价格
涨跌幅

ENTA 简况

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
展开

微牛提供Enanta Pharmaceuticals Inc(NASDAQ-ENTA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ENTA股票新闻,以帮助您做出投资决策。